

## Product Update:

paliperidone palmitate 175mg, 263mg, 350mg, 525mg prolonged release  
suspension for injection (Trevicta<sup>®</sup>) SMC No. (1181/16)

Janssen-Cilag Ltd

05 August 2016

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**paliperidone palmitate (Trevicta<sup>®</sup>)** is accepted for use within NHS Scotland.

**Indication under review:** paliperidone palmitate (Trevicta<sup>®</sup>), a three-monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on one-monthly paliperidone palmitate injectable product.

This new formulation of paliperidone palmitate is administered every three months and is available at pro-rata cost to the monthly formulation.

### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 07 June 2016.*

**Chairman**  
**Scottish Medicines Consortium**